Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Kissei claims SGLT2 inhibitors for use in diabetes and obesity

June 17, 2002

Novo Nordisk presents structurally novel DPP-IV inhibitor

June 14, 2002

Vasopressin/oxytocin antagonists and their use in preterm labor, etc.

June 14, 2002

New growth hormone secretagogues claimed by Lilly

June 14, 2002

I2S gives positive results in phase I/II Hunter's syndrome study

June 13, 2002

Guggulsterone effectively reduces cholesterol via antagonism of FXR receptor

June 13, 2002

New GSK-3 inhibitors in early development at Novo Nordisk

June 13, 2002

beta3-Adrenoceptor agonists and their use in obesity, diabetes, etc.

June 13, 2002

Wyeth discontinues development of PTP-112

June 12, 2002

Transkaryotic Therapies broadens intellectual property in Gaucher's and Fabry's diseases

June 12, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...